Drug Development Summaries
Dai, Yanan ; Fremont, Daved ; Harvey, Ian ; Nelson, Christopher ; Zhao, Haiyan
T-019413
— A number of bacterial and mammalian expression vectors for production of SARS-CoV proteins that can be used for immunization, B-cell sorting, and human serum evaluation are available. Expression constructs produce: spike, ACE2, CD147, Surface display, SARS-1 and SARS-2 ORF7a, ORF8, and nucleocapsid…
SARS-CoV-2 neutralizing antibodies with distinct epitopes effective against multiple variantsEllebedy, Ali
T-019707
— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized these antibodies, creating a chimeric version with a human IgG backbone for SARS2-38. The antibodies have …
SARS-CoV-2 neutralizing antibody effective against all variantsAdams, Lucas ; Diamond, Michael ; Fremont, Daved ; VanBlargan, Laura
T-019791
— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format – Chimeric monoclonal antibody Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…
Molecular imaging of COVID binding receptorAbou, Diane ; Thorek, Daniel ; Zhang, Hanwen
T-019485
— Technology Description A team of researchers led by Professor Daniel Thorek at Washington University have developed a peptide specific to human ACE2, the receptor for SARS-CoV-2, that can be used for imaging or therapeutic delivery. The peptide can be easily chelated for PET imaging, allowing for …